NTT-COMMUNICATIONS
8.4.2021 04:02:11 CEST | Business Wire | Press release
NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group, announced today that it has succeeded in a trial sharing of production-line data related to CO2 emissions via a prototype platform that enables interconnection via IDS standards which support data sovereignty in GAIA-X data ecosystem. The trial data, which normally would not be available for sharing due to its high confidentiality even though partners engaged in actual business would need to perform CO2 emissions calculations, was transmitted securely to designated sites in Germany and Japan from Switzerland Innovation Park Biel/Bienne in Switzerland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210407006040/en/
GAIA-X is an initiative announced by the German and French governments in October 2019 to support data sharing via infrastructure that ensures data protection, transparency, reliability and interoperability to protect the rights of European companies, governments, institutions and citizens.
NTT Com conducted the trial under the assumption that such data will be used by companies engaged in actual business to review their manufacturing methods to achieve greater decarbonization. The prototype platform, which enables interconnection with IDS Connectors, also is equipped with DATA Trust® , a mechanism for the secure sharing of highly confidential data.
The trial involved the sharing of electricity-consumption data that business partners typically would use to calculate CO2 emissions generated during the manufacturing of specific products. The trial confirmed that NTT’s platform can share such data securely with only those parties permitted by law or contract.
The prototype was developed using Nippon Telegraph and Telephone Corporation (Software Innovation Center)'s business-to-business data distribution technology, in cooperation with Robot Revolution & Industrial IoT Initiative (RRI), International Data Spaces Association (IDSA), Fraunhofer-Gesellschaft, Switzerland Innovation Park Biel/Bienne and Japan Innovation Park.
NTT Com plans to exhibit the trial results at the joint booth of IDSA and RRI during the Hannover Messe industrial fair in Germany from April 12-16.
“Japan is very close to Europe in the field of industry, with a strong experience in automotive, steel, or manufacturing,” said Hubert Tardieu, Chairman of GAIA-X AISBL. “The main objective in every industry is nowadays data sharing and service orchestration like in GAIA-X. NTT Communications starts with a first run in data sharing between, Japan, Germany and Switzerland, using the IDS standard which supports data sovereignty in GAIA-X data ecosystems. We are proud at GAIA-X AISBL to strongly support the launching of the japan Hub trough NTT Communications and start more use cases around GAIA-X.”
Going forward, NTT Com will build a test environment in Japan to connect with GAIA-X and start interoperability tests with multiple partner companies around the world this summer. If all goes well, NTT Com hopes to launch an official platform within the fiscal year ending in March 2022. The launch would be coordinated with organizations and groups involved with international data distribution, including Data Society Alliance, OPC Foundation Japan, RRI, GAIA-X AISBL and IDSA.
Data utilization has become indispensable for initiatives such as global decarbonization, the early achievement of the United Nations’ Sustainable Development Goals and the strengthening of industries. At the same time, however, legal systems and technologies to regulate and manage data use are being developed around the world, one of which is GAIA-X, to prevent the leakage of corporate and national secrets and to protect data sovereignty.
In the future, it is expected that companies will be required to use GAIA-X to send and receive highly confidential data to and from business partners in European countries. This means that companies unable to use GAIA-X would not be able to do business with European partners if sensitive data sharing were involved. NTT Com’s envisioned platform, however, would enable such companies to easily connect to GAIA-X without have to spend valuable time and money on an acceptable data-sharing solution.
About NTT Communications
NTT Communications solves the world's technology challenges by helping enterprises overcome complexity and risk in their ICT environments with managed IT infrastructure solutions. These solutions are backed by our worldwide infrastructure, including industry leading, global tier-1 public and private networks reaching over 190 countries/regions, and more than 500,000m2
of the world's most advanced data center facilities. Our global professional services teams provide consultation and architecture for the resiliency and security required for your business success, and our scale and global capabilities in technology world are unsurpassed. Combined with NTT Ltd., NTT Data, and NTT DOCOMO, we are NTT Group.
www.ntt.com
| Twitter@NTT Com | Facebook@NTT Com | LinkedIn@NTT Com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407006040/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
